2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatients
2012
Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer.
Greenup R, Bardia A, Buckley J, Niemierko A, Camp M, Coopey S, Gadd M, Schapira L, Taghian A, Smith B, Specht M. Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. Journal Of Clinical Oncology 2012, 30: 1122-1122. DOI: 10.1200/jco.2012.30.15_suppl.1122.Peer-Reviewed Original ResearchPathologic complete responseNeoadjuvant chemotherapyOverall survivalBreast cancerComplete responseYoung womenAdjuvant chemotherapyHazard ratioHER-2Stage IYoung breast cancer patientsTriple-negative breast cancerNeo-adjuvant chemotherapyTiming of chemotherapyBreast cancer patientsState tumor registryFinal pathologic reviewDeath certificate dataNegative breast cancerValuable surrogate markerOS ratesPathologic reviewSystemic therapyTumor RegistryDeath Index